New insider activity at RenovoRx ( (RNXT) ) has taken place on May 21, 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
RenovoRx’s Chief Financial Officer, Mark Voll, has increased his stake in the company by purchasing 25,000 shares of RenovoRx stock in a recent transaction. The total value of this insider buy amounts to $19,500, signaling a tangible financial commitment from the company’s top financial executive.
Recent Updates on RNXT stock
RenovoRx shares reacted to its Q1 earnings, where revenue and margins exceeded expectations, signaling accelerating adoption of its RenovoCath device and attractive unit economics. Analysts’ price target revisions likely centered on record revenue growth, expanding center footprint, and extended cash runway into 2H 2027, balanced against modest absolute revenue, high operating burn, and execution risk in completing the TIGeR-PaC Phase III trial and converting pipeline centers into steady procedure volume.
Spark’s Take on RNXT Stock
According to Spark, TipRanks’ AI Analyst, RNXT is a Neutral.
The score is held back primarily by weak financial performance (large losses and sustained cash burn) and bearish technicals (below key moving averages with negative MACD). Offsetting these are constructive earnings-call signals—reiterated revenue guidance, strong gross margins, expanding commercial footprint, and extended cash runway—though valuation remains difficult to support given ongoing losses and no stated dividend yield.
To see Spark’s full report on RNXT stock, click here.
More about RenovoRx
YTD Price Performance: -3.57%
Average Trading Volume: 354,946
Technical Sentiment Signal: Sell
Current Market Cap: $36.5M